Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole was unchanged today. By the end of trading, Allergan fell $2.00 (-2.2%) to $90.26 on light volume. Throughout the day, 2,209,684 shares of Allergan exchanged hands as compared to its average daily volume of 3,079,300 shares. The stock ranged in price between $90.08-$92.07 after having opened the day at $92.07 as compared to the previous trading day's close of $92.26. Other companies within the Drugs industry that declined today were:
), down 37.9%,
), down 8.2%,
), down 8.1% and
), down 6.9%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass
Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $27.1 billion and is part of the health care sector. Shares are down 0.2% year to date as of the close of trading on Friday. Currently there are 11 analysts that rate Allergan a buy, no analysts rate it a sell, and 12 rate it a hold.
TheStreet Ratings rates
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
- You can view the full Allergan Ratings Report.
On the positive front,
), up 54.8%,
), up 41.3%,
), up 38.0% and
), up 17.0% , were all gainers within the drugs industry with
) being today's featured drugs industry leader.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
) while those bearish on the drugs industry could consider
- Find other investment ideas from our top rated ETFs lists.